Communications Medicine· 2026Q1

Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials

Anne Sophie Kubasch, Katharina Zoldan, Dominic Brauer, Philipp Kiewe et al.

0citations
Q1SCImago
2026year

Short summary

Neither canakinumab nor emavusertib achieved the primary endpoint of hematologic improvement in patients with lower-risk myelodysplastic neoplasms (MDS) in the CANFIRE and LUCAS phase 2 trials, respectively.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine